0
C-suite operators and physician leaders
Strategic Execution Partner
Lakeland Strategic Partners helps healthcare and medtech organizations accelerate commercialization, strengthen operating performance, and scale with discipline. We bridge clinical authority, financial rigor, and execution systems that move from strategy to measurable results.
0
C-suite operators and physician leaders
0
Years of senior operations track record represented in leadership
0
Execution phases from assessment through scale
Who We Are
We are not a slide-only advisory firm. Lakeland deploys implementation-grade strategy for growth-stage and transformation-stage businesses that cannot afford execution drift.
Our leadership bench includes physician executives, commercialization operators, and transformation leaders with direct experience in clinical adoption, revenue-cycle optimization, and platform scale-up.
What We Do
Market entry strategy, channel sequencing, pricing discipline, and launch governance designed for measurable adoption.
KOL activation, value-analysis alignment, outcomes instrumentation, and clinical-commercial integration that de-risks scale.
End-to-end process redesign, ERP/CRM workflow modernization, and performance management tied to margin and throughput.
Strategic diligence support, value-creation thesis refinement, and execution planning for sponsors, operators, and portfolio teams.
Watchlist Opportunity
Supercritical CO2 tissue processing with strong ECM preservation, faster cycle times, and a differentiated quality profile versus legacy chemical wash approaches.
Structured launch path built around Section 361 positioning for selected categories, AATB progression, and staged U.S. commercial deployment.
Phased execution from rights acquisition and initial channel launch through KOL validation, hospital system expansion, and strategic platform growth.
Engagement Model
2-4 week assessment of market, operations, and regulatory realities.
30-90 day operating plan with owners, metrics, and risk controls.
Controlled deployment to generate adoption data and financial signal.
Repeatable rollout model, governance cadence, and KPI-driven expansion.
Platform Spotlight
Through leadership collaboration with Medici BioStrategy and BioDOF, the team has shaped a North American commercialization thesis around a supercritical CO2 tissue platform with validated implant history and a clear regulatory strategy for disciplined launch and scale.
Reported successful implants in referenced program data
Top-tier hospitals represented in prior regional deployment
Target launch window referenced in milestone planning
Leadership
All six founding leaders are in the same Executive MBA cohort graduating in May 2026.
Chief Executive Officer
Board-certified reconstructive surgeon, Associate Professor, and UH Ventures medical director focused on medtech strategy and commercialization.
Chief Operating Officer
Senior operations leader and U.S. military veteran driving systems integration, execution discipline, and EBITDA-focused transformation.
Chief Financial Officer
Physician advisor and associate professor focused on quality, safety, reimbursement optimization, and financial stewardship.
Chief Technology Officer
Pulmonary and critical care physician-executive and finance-trained strategist leading AI-enabled clinical operations and enterprise transformation.
Chief Transformation & Marketing Officer (CTMO)
Orthopaedic division head and surgeon with deep clinician behavior, medtech differentiation, and platform scalability insight.
Chief Innovation Officer
Clinician-scientist and strategic advisor with translational research depth and enterprise innovation perspective.
Let's Build The Next Platform
For strategic advisory, commercialization, operating transformation, or diligence support, we can start with an executive scoping call.
hello@lakelandstrategicpartners.com